retatrutide side effects clinical trial results 2024 2025 Results: 28.3% Weight Loss Data Lilly's triple agonist achieves 16.8%

If pancreatitis is confirmed, the medication should be permanently discontinued and not restarted

Participants were predominantly male and African-American

Despite its benefits, the clinical application of orlistat is often hindered by its gastrointestinal side effects and modest weight loss results, prompting the search for alternative and adjunct therapies, including natural products and novel PL inhibitory peptides that may offer better tolerability and effectiveness in managing obesity [7,8,9]

Here's why this matters: The Adherence Problem Injectable cholesterol drugs work brilliantly

References Clayton AH et al